NCT05155189View on ClinicalTrials.gov

A Study to Evaluate Safety and Efficacy of Armored CAR-T Cell Injection C-CAR031 in Advanced Hepatocellular Carcinoma

PHASE1RecruitingINTERVENTIONAL
Enrollment

44

Participants

Timeline

Start Date

December 9, 2021

Primary Completion Date

May 31, 2026

Study Completion Date

May 31, 2041

Conditions
Hepatocellular Carcinoma
Interventions
BIOLOGICAL

C-CAR031

Targeting GPC3 armored CART cell injection (C-CAR031)

DRUG

Lenvatinib

Tyrosine kinase inhibitors

DRUG

PD-1(L1) monoclonal antibody

Immune checkpoint inhibitors, ICIs

Trial Locations (2)

310003

RECRUITING

the First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou

Unknown

RECRUITING

The first affiliated hospital of Zhengzhou University, Zhengzhou

All Listed Sponsors
lead

Zhejiang University

OTHER